Intravitreal bevacizumab during pregnancy

Retina

Volumn 30, Issue 9, 2010, Pages 1405-1411

  Tarantola, Ryan M ^a   Folk, James C ^a   Boldt, H Culver ^a   Mahajan, Vinit B ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Avastin; bevacizumab; pregnancy

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; BREAST FEEDING; CASE REPORT; DELIVERY; FEMALE; FOLLOW UP; GESTATION PERIOD; HUMAN; PREGNANCY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; EYE INFECTIONS, FUNGAL; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HISTOPLASMOSIS; HUMANS; INTRAVITREAL INJECTIONS; OFF-LABEL USE; PREGNANCY; PREGNANCY COMPLICATIONS; SARCOIDOSIS; TOMOGRAPHY, OPTICAL COHERENCE; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77958563770     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181f57d58     Document Type: Article

References (35)

1. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511. (Pubitemid 44620390)
2. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390 (Pubitemid 44197628)
3. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113: 363-372.
4. Fung AE, Rosenfeld PJ, Reichel E. The International Intra-vitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349. (Pubitemid 44702055)
5. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
6. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-376.
7. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114: 2190-2196.
8. Mandal S, Garg S, Venkatesh P, Mithal C, Vohra R, Mehrotra A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007;125:1487-1492. (Pubitemid 350106680)
9. Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaks. Eye (Lond) 2008;22:734-735. (Pubitemid 351712380)
10. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-1186. (Pubitemid 350211522)
11. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroid-opathy, or of idiopathic origin. Am J Ophthalmol 2007;143: 977-983.
12. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008;145:875-878.
13. Ahmadieh H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007;245:1731-1733. (Pubitemid 47491566)
14. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-1579. (Pubitemid 47126590)
15. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 2007;245:917-918. (Pubitemid 46805628)
16. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemi-central retinal vein occlusions: IBeVO study. Retina 2007;27: 141-149. (Pubitemid 46245639)
17. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
18. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695, e1-e15. (Pubitemid 44442453)
19. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.
20. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.
21. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevaci-zumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508. (Pubitemid 46243494)
22. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
23. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729. (Pubitemid 350086473)
24. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
25. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
26. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6: 465-477.
27. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:1379-1381.
28. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
29. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-543.
30. Final labeling text, highlights of prescribing information. U.S. BL 125085/168 Amendment: Bevacizumab-Genentech, Inc. Updated July 2009. South San Francisco, CA: Genentech, Inc. http://www.gene.com/gene/products/information/ pdf/avastin-prescribing.pdf. Accessed September 10, 2010.
31. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009;86:328-344.
32. Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (Lond) 2009;23:1479.
33. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. In press. doi: 10.1111/j.1755-3768.2009.01572.x.
34. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319:189-194.
35. Van de Perre P. Transfer of antibody via mother's milk. Vaccine 2003;21:3374-3376 (Pubitemid 36792089)